Review



anti chrebp antibody  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    Novus Biologicals anti chrebp antibody
    Experimental validation of MLXIPL upregulation and metabolic network consistency in diabetic models. (A–C) Assessment of <t>ChREBP</t> expression in kidney tissues from db/m and db/db mice. Representative Western blots (A) and densitometric quantification (B) of ChREBP protein levels. For animal Western blot analyses, densitometric quantification was performed using all 12 mice per group. Full-length immunoblot images are provided in <xref ref-type=Supplementary Figure 4 . (C) Relative mRNA expression of Mlxipl . (D–F) Assessment of ChREBP expression in primary proximal tubular epithelial cells (PTECs) under normal glucose (NC) and high glucose (HG) conditions. Representative Western blots (D) , protein quantification (E) , and mRNA levels (F) . (G) Representative immunohistochemistry (IHC) staining of ChREBP in mouse kidney sections. Scale bar: 100 μm. (H) Representative immunofluorescence (IF) staining of ChREBP (green) in PTECs; nuclei were counterstained with DAPI (blue). Scale bar: 50 μm. (I) Relative mRNA expression of MLXIPL -interacting metabolic genes in mouse kidneys. (J) Pearson correlation analysis between Mlxipl expression and downstream metabolic targets in kidney tissues.Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. " width="250" height="auto" />
    Anti Chrebp Antibody, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 95/100, based on 109 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti chrebp antibody/product/Novus Biologicals
    Average 95 stars, based on 109 article reviews
    anti chrebp antibody - by Bioz Stars, 2026-06
    95/100 stars

    Images

    1) Product Images from "Integrated causal inference, kidney transcriptomics, and experimental validation identify ChREBP ( MLXIPL ) as a driver of maladaptive metabolic remodeling in diabetic kidney disease"

    Article Title: Integrated causal inference, kidney transcriptomics, and experimental validation identify ChREBP ( MLXIPL ) as a driver of maladaptive metabolic remodeling in diabetic kidney disease

    Journal: Frontiers in Endocrinology

    doi: 10.3389/fendo.2026.1809567

    Experimental validation of MLXIPL upregulation and metabolic network consistency in diabetic models. (A–C) Assessment of ChREBP expression in kidney tissues from db/m and db/db mice. Representative Western blots (A) and densitometric quantification (B) of ChREBP protein levels. For animal Western blot analyses, densitometric quantification was performed using all 12 mice per group. Full-length immunoblot images are provided in <xref ref-type=Supplementary Figure 4 . (C) Relative mRNA expression of Mlxipl . (D–F) Assessment of ChREBP expression in primary proximal tubular epithelial cells (PTECs) under normal glucose (NC) and high glucose (HG) conditions. Representative Western blots (D) , protein quantification (E) , and mRNA levels (F) . (G) Representative immunohistochemistry (IHC) staining of ChREBP in mouse kidney sections. Scale bar: 100 μm. (H) Representative immunofluorescence (IF) staining of ChREBP (green) in PTECs; nuclei were counterstained with DAPI (blue). Scale bar: 50 μm. (I) Relative mRNA expression of MLXIPL -interacting metabolic genes in mouse kidneys. (J) Pearson correlation analysis between Mlxipl expression and downstream metabolic targets in kidney tissues.Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. " title="... network consistency in diabetic models. (A–C) Assessment of ChREBP expression in kidney tissues from db/m and db/db ..." property="contentUrl" width="100%" height="100%"/>
    Figure Legend Snippet: Experimental validation of MLXIPL upregulation and metabolic network consistency in diabetic models. (A–C) Assessment of ChREBP expression in kidney tissues from db/m and db/db mice. Representative Western blots (A) and densitometric quantification (B) of ChREBP protein levels. For animal Western blot analyses, densitometric quantification was performed using all 12 mice per group. Full-length immunoblot images are provided in Supplementary Figure 4 . (C) Relative mRNA expression of Mlxipl . (D–F) Assessment of ChREBP expression in primary proximal tubular epithelial cells (PTECs) under normal glucose (NC) and high glucose (HG) conditions. Representative Western blots (D) , protein quantification (E) , and mRNA levels (F) . (G) Representative immunohistochemistry (IHC) staining of ChREBP in mouse kidney sections. Scale bar: 100 μm. (H) Representative immunofluorescence (IF) staining of ChREBP (green) in PTECs; nuclei were counterstained with DAPI (blue). Scale bar: 50 μm. (I) Relative mRNA expression of MLXIPL -interacting metabolic genes in mouse kidneys. (J) Pearson correlation analysis between Mlxipl expression and downstream metabolic targets in kidney tissues.Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

    Techniques Used: Biomarker Discovery, Expressing, Western Blot, Immunohistochemistry, Immunofluorescence, Staining



    Similar Products

    anti chrebp antibody  (Novus Biologicals)
    95
      Buy from Supplier
    anti chrebp  (Cell Signaling Technology Inc)
    94
      Buy from Supplier
    chrebp  (Santa Cruz Biotechnology)
    94
      Buy from Supplier
    chrebp  (Novus Biologicals)
    94
      Buy from Supplier
    chrebp  (Proteintech)
    93
      Buy from Supplier

    Image Search Results


    Experimental validation of MLXIPL upregulation and metabolic network consistency in diabetic models. (A–C) Assessment of ChREBP expression in kidney tissues from db/m and db/db mice. Representative Western blots (A) and densitometric quantification (B) of ChREBP protein levels. For animal Western blot analyses, densitometric quantification was performed using all 12 mice per group. Full-length immunoblot images are provided in <xref ref-type=Supplementary Figure 4 . (C) Relative mRNA expression of Mlxipl . (D–F) Assessment of ChREBP expression in primary proximal tubular epithelial cells (PTECs) under normal glucose (NC) and high glucose (HG) conditions. Representative Western blots (D) , protein quantification (E) , and mRNA levels (F) . (G) Representative immunohistochemistry (IHC) staining of ChREBP in mouse kidney sections. Scale bar: 100 μm. (H) Representative immunofluorescence (IF) staining of ChREBP (green) in PTECs; nuclei were counterstained with DAPI (blue). Scale bar: 50 μm. (I) Relative mRNA expression of MLXIPL -interacting metabolic genes in mouse kidneys. (J) Pearson correlation analysis between Mlxipl expression and downstream metabolic targets in kidney tissues.Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. " width="100%" height="100%">

    Journal: Frontiers in Endocrinology

    Article Title: Integrated causal inference, kidney transcriptomics, and experimental validation identify ChREBP ( MLXIPL ) as a driver of maladaptive metabolic remodeling in diabetic kidney disease

    doi: 10.3389/fendo.2026.1809567

    Figure Lengend Snippet: Experimental validation of MLXIPL upregulation and metabolic network consistency in diabetic models. (A–C) Assessment of ChREBP expression in kidney tissues from db/m and db/db mice. Representative Western blots (A) and densitometric quantification (B) of ChREBP protein levels. For animal Western blot analyses, densitometric quantification was performed using all 12 mice per group. Full-length immunoblot images are provided in Supplementary Figure 4 . (C) Relative mRNA expression of Mlxipl . (D–F) Assessment of ChREBP expression in primary proximal tubular epithelial cells (PTECs) under normal glucose (NC) and high glucose (HG) conditions. Representative Western blots (D) , protein quantification (E) , and mRNA levels (F) . (G) Representative immunohistochemistry (IHC) staining of ChREBP in mouse kidney sections. Scale bar: 100 μm. (H) Representative immunofluorescence (IF) staining of ChREBP (green) in PTECs; nuclei were counterstained with DAPI (blue). Scale bar: 50 μm. (I) Relative mRNA expression of MLXIPL -interacting metabolic genes in mouse kidneys. (J) Pearson correlation analysis between Mlxipl expression and downstream metabolic targets in kidney tissues.Data are presented as mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.

    Article Snippet: Sections were blocked with 1% BSA and incubated with anti-ChREBP antibody (Novus Biologicals, NB400-135; IHC dilution 1:200), followed by appropriate secondary antibodies and chromogenic development.

    Techniques: Biomarker Discovery, Expressing, Western Blot, Immunohistochemistry, Immunofluorescence, Staining